About Erbi Biosystems

Erbi Biosystems supports therapeutic drug manufacturers with tools to accelerate the development of their processes and therapies. Erbi’s technology platform includes single-use, mL-scale cell culture, microfluidics, optical sensing, and integrated controls.

The Breez bioreactor is used across a range of applications and cell types, including media and cell-line development; intensified process and n-1; CAR-T process development; and non-mammalian cell culture. The small size, single-use device, and fully automated operation drastically reduce the time, media consumption and lab space required for process development. The mL-scale working volume and closed-sterile consumable format make it ideal when working with scarce and highly variable source materials, such as autologous therapy development.

The Erbi Breez system is available worldwide with sales and distribution in the US, EU, and China.

Leadership Teams

President and CEO

Michael Chiu, Ph.D.

Dr. Chiu has joined Erbi in 2018 as COO. He has over 25 years of experience in development of innovative and early-stage technologies across multiple industries

Dr. Chiu has joined Erbi in 2018 as COO. He has over 25 years of experience in development of innovative and early-stage technologies across multiple industries including semiconductors, optics and life sciences. Prior to joining Erbi, Michael was CTO/VP Engineering at AEi/Mycronic, co-founded Gecko Health and founded Trophos Energy all of which were acquired or sold. He started his career at Teradyne, where he rose to the position of General Manager. Michael earned BSME from the University of Minnesota and MSME, PhD and MBA degrees from the Massachusetts Institute of Technology. Michael has multiple patents and is the recipient of an R&D 100 award.
Head of Cell & Gene Therapy & Bioprocess Applications Development

Kevin Lee, Ph.D.

Dr. Lee formally joined Erbi as co-founder in 2011 but helped develop the core technology platform with Dr. Harry Lee as part of his doctoral research,

Dr. Lee formally joined Erbi as co-founder in 2011 but helped develop the core technology platform with Dr. Harry Lee as part of his doctoral research, which included design of continuous flow microbioreactors and development of a proprietary and patented plastic bonding process that is an enabling technology in Erbi’s bioreactor platform. Kevin also is expert in embedded systems, cell culture and bioengineering and has a B.S.E.E. from the University of California, Los Angeles and a PhD from the Massachusetts Institute of Technology. Kevin is inventor on 6 patents, and has led programs with industry and academia across multiple cell types including e.coli, Pichia, CHO and CAR-T.
Director of Systems Engineering

Blair Morad

Mr. Morad has over 20 years in product development, with 15 years in the life science industry, including cell sorting, cell culturing, and microbial detection.

Mr. Morad has over 20 years in product development, with 15 years in the life science industry, including cell sorting, cell culturing, and microbial detection. Blair has directed multi-discipline teams in creating industry recognized products at Cytonome, Emulate Bio, and most recently Director of New Product Development at Rapid Micro Biosystems, a leader in automated QC microbial detection. Blair has a BSME from the University of Massachusetts, Amherst.
Co-Founder and CTO

Harry Lee, Ph.D.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years. Harry has deep expertise in systems engineering, photonics, embedded systems, cell culture and bioengineering. He has a B.S.E.E. from the University of Michigan and a PhD from the Massachusetts Institute of Technology. Harry is inventor on 8 patents, is the author of multiple publications in the field and has been awarded multiple grants to further develop Erbi’s core technology.
VP of Product Management and Business Development

John Bonham-Carter

Mr. Bonham-Carter is recognized as one of the early pioneers making continuous bioprocessing a manufacturing reality through Refine’s ATF System

Mr. Bonham-Carter is recognized as one of the early pioneers making continuous bioprocessing a manufacturing reality through Refine’s ATF System – a company he sold to Repligen in 2014. Subsequently within Repligen, he forged the future of intensified processing, ensuring that all processes could benefit from exceptionally high productivity processes. Over 20 therapeutic products, from vaccines to gene therapies and proteins, are now commercially manufactured with products that John brought to market. John has edited 2 books on this subject.

John has broad entrepreneurial, product development and BD experience ranging from AI in fermentation prediction, multiple analytical technologies, metabolic modelling and impact on facilities due to process improvement. He is sought after as a technically focused expert to bring new technologies to market and has been a regular international speaker and co-organizer of several cell culture conferences. He now advises several companies and is an active Angel investor.

Operations Manager

Conor McCarron

Conor McCarron manages manufacturing, supply chain, and logistics for Erbi Biosystems. Prior to joining Erbi he spent seven years working in operations and manufacturing engineering

Conor McCarron manages manufacturing, supply chain, and logistics for Erbi Biosystems. Prior to joining Erbi he spent seven years working in operations and manufacturing engineering at Raytheon Integrated Defense Systems where he primarily worked on the manufacturing of high voltage assemblies and radio frequency circuit boards. Conor holds a Bachelors of Science in Mechanical Engineering and Electrical Engineering, as well as a Masters of Engineering In Manufacturing Engineering from Boston University.
Chief Scientific Officer

Brad Hamilton

Brad Hamilton, is the founder and Chief Science Officer at GoodCell, where he oversees all of GoodCell’s scientific programs and technologies. Prior to joining GoodCell, Brad

Brad Hamilton, is the founder and Chief Science Officer at GoodCell, where he oversees all of GoodCell’s scientific programs and technologies. Prior to joining GoodCell, Brad was the Chief Technology Officer for ReproCELL, a multinational stem cell company focused on developing novel stem cell technologies and therapies.

Brad’s work as a founding scientist and director of research for Stemgent helped to develop groundbreaking RNA-mediated cellular reprogramming technologies, as well as applications for the generation of induced pluripotent stem cells from clinically accessible samples such as human skin, blood, and urine.

Brad has both published and presented this work internationally. He is a member of the International Society of Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT). Prior to joining the field of stem cell research, Brad led research programs at RheoGene and Upstate Biotech (acquired by Millipore), focusing on developing novel discovery technologies such as orthogonal, inducible mammalian gene expression switches, and RNAi screening platforms.

Brad holds an MS in biotechnology from the University of Tennessee—Knoxville, as well as a BS in biology from James Madison University.

VP of Sales

Shelly Adams

Shelly Adams directs the commercial development, sales, and marketing functions within Erbi Biosystems. During her distinguished career

Shelly Adams directs the commercial development, sales, and marketing functions within Erbi Biosystems. During her distinguished career of more than 25 years, she has led commercial efforts within the medical device, biotech, pharmaceutical, and contract manufacturing industries. Her passion, creativity, and commitment to satisfy customer needs have led to a remarkable reputation in the industry. Prior to joining Erbi Biosystems, Shelly worked for Abzena, Gallus BioPharmaceuticals, Johnson Mathey, and Avecia Biologics in the CDMO marketplace. During her time in contract manufacturing companies, her sales experience included developing and manufacturing monoclonal antibodies, DNA medicines, microbial biologics, and small molecules. Shelly holds a bachelor’s in Biology from the University of California, San Diego, USA.

Michael Chiu, Ph.D.

Dr. Chiu has joined Erbi in 2018 as COO. He has over 25 years of experience in development of innovative and early-stage technologies across multiple industries including semiconductors, optics and life sciences. Prior to joining Erbi, Michael was CTO/VP Engineering at AEi/Mycronic, co-founded Gecko Health and founded Trophos Energy all of which were acquired or sold. He started his career at Teradyne, where he rose to the position of General Manager. Michael earned BSME from the University of Minnesota and MSME, PhD and MBA degrees from the Massachusetts Institute of Technology. Michael has multiple patents and is the recipient of an R&D 100 award.

Harry Lee, Ph.D.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years. Harry has deep expertise in systems engineering, photonics, embedded systems, cell culture and bioengineering. He has a B.S.E.E. from the University of Michigan and a PhD from the Massachusetts Institute of Technology. Harry is inventor on 8 patents, is the author of multiple publications in the field and has been awarded multiple grants to further develop Erbi’s core technology.

John Bonham-Carter

Mr. Bonham-Carter is recognized as one of the early pioneers making continuous bioprocessing a manufacturing reality through Refine’s ATF System – a company he sold to Repligen in 2014. Subsequently within Repligen, he forged the future of intensified processing, ensuring that all processes could benefit from exceptionally high productivity processes. Over 20 therapeutic products, from vaccines to gene therapies and proteins, are now commercially manufactured with products that John brought to market. John has edited 2 books on this subject.

John has broad entrepreneurial, product development and BD experience ranging from AI in fermentation prediction, multiple analytical technologies, metabolic modelling and impact on facilities due to process improvement. He is sought after as a technically focused expert to bring new technologies to market and has been a regular international speaker and co-organizer of several cell culture conferences. He now advises several companies and is an active Angel investor.

Joe Gentile

Mr. Gentile has over 30 years of global medical device, diagnostics and life science experience driving growth in developed and emerging markets, enhancing profitability and cash flow, achieving operational excellence, and developing next generation products, services and technologies.  He served on the board or TIE Boston and currently advises multiple life science ventures helping them from startup to successful exit.  Joe has a BSEE from Northeastern University as well as an MSEE and MBA from Boston University.

Mark Erhrman

Dr. Ehrman is an expert in oncology and has built, run and sold an extensive medical practice in this field. He currently develops commercial properties and other investments. Mark has a BA in Mathematics from Princeton University, MSc in Microbiology and Chemistry from NYU, an MD from NYU School of Medicine and a JD from Boston University School of Law.

Thomas C. Ransohoff, M.S

Thomas C. Ransohoff, M.S is currently Co-Head, Biologicals Franchise at National Resilience, Inc. (“Resilience”) and has over 30 years of experience in the biopharmaceutical industry. Mr. Ransohoff’s areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Before joining Resilience, Mr. Ransohoff was a Managing Director at BDO and its precursor BPTC, a leading CMC consulting firm that he helped build over a 20 year period. Prior to that, he held senior level positions at TranXenoGen, Dyax, Repligen, and Xoma. He is also a co-founder of several successful start-ups, including 4th Dimension Bioprocess, Tarpon Biosystems and BioFlash Partners. He serves on a number of scientific and professional advisory boards and holds a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.

Rod Rietze, Ph.D.

Dr. Rod Rietze is co-founder and CEO of iVexSol (intelligent Vector Solutions), Inc., a burgeoning viral vector manufacturer founded on a transformative technology that enables the production of stable lentiviral vectors at any scale. Prior to iVexSol, Rod was the Director of Strategic Development and Innovation at Novartis Cell and Gene Therapy (Cambridge, MA), where he supported the clinical development of a number of next-generation cell and gene therapies, including Kymriah™, the first FDA-approved CAR-T cell-based gene therapy.

Before joining Novartis, Rod led research and development teams of both small molecule and cell-based therapeutics at Pfizer Regenerative Medicine (Cambridge, UK) and TxCell SA (Sophia Antipolis, France). During his tenure in academia, Rod co-founded the 400-member Queensland Brain Institute (Brisbane, Australia), where his lab focused on harnessing the regenerative capacity of resident neural stem cells as a means to treat age-related cognitive decline. His work was featured on the front covers of Nature and Science, and received numerous awards including Science Magazine’s “Breakthrough of the Year”.

With over two decades of technical, operational, and strategic leadership experience in the development of novel therapeutics, Rod remains passionate about discovering and delivering innovative technologies and medicines to transform the treatment of disease. He holds a BSc and MSc from the University of Calgary, Canada, and a Ph.D. from The Walter and Eliza Hall Institute of Medical Research (University of Melbourne, Australia).

Bert Frohlich, Ph.D.

Bert Frohlich is a Ph.D. biochemical engineer with over 25 years of experience in the biotechnology, pharmaceutical, and chemical industries; he has been consulting through his own company, Biopharm Designs LLC, for the last four years. Although most of his experience is in the biopharmaceutical CMC space, he served most recently as Vice President of Engineering and Commercialization at BlueNalu Inc., a startup company in the new cell-based meat area. Before becoming a consultant, he held director-level positions at Shire, Amgen, EMD, and Acambis (now Sanofi) and worked as a senior engineer at Genzyme, Biometics, and Roche in process/facility design, bioprocess development, and manufacturing technical services. Over the course of his career, Bert introduced a variety of products to manufacturing through the scale-up and tech transfer of cell culture and other processes. In addition to advising on strategic direction in process and manufacturing technology, he now also helps clients design and implement high-level business processes, including cost modeling and quality-by-design, towards improving work efficiency, costs, timelines, and product quality.

Rajeev J. Ram

Rajeev J. Ram has worked in the areas of physical optics and electronics for much of his career. In the early 1990’s, he developed the III‑V wafer bonding technology that led to record brightness light emitting devices at Hewlett-Packard Laboratory in Palo Alto. While at HP Labs, he worked on the first commercial deployment of surface emitting lasers. In the early 1990’s, he developed the first semiconductor laser without population inversion, semiconductor lasers that employ condensation of massive particles, and threshold-less lasers.

Since 1997, Ram has been on the Electrical Engineering faculty at the Massachusetts Institute of Technology (MIT) and a member of the Research Laboratory of Electronics. He has served on the Defense Sciences Research Council advising DARPA on new areas for investment and served as a Program Director at the newly founded Advanced Research Project Agency-Energy. At ARPA‑e, he managed a research portfolio exceeding $100M and consulted with the Office of Science and Technology Policy and the White House.

His group at MIT has developed record energy-efficient photonics for microprocessor systems, microfluidic systems for the control of cellular metabolism, and the first light-source with greater than 100% electrical-to-optical conversion efficiency. His group’s work on small-scale solar thermoelectric generation is being deployed for rural electrification in the developing world as SolSource and was recognized with the St. Andrews Prize for Energy and the Environment.

Ram holds degrees in Applied Physics from California Institute of Technology and Electrical Engineering from the University of California, Santa Barbara.

Senior Leadership Team
President and CEO

Michael Chiu, Ph.D.

Dr. Chiu has joined Erbi in 2018 as COO. He has over 25 years of experience in development of innovative and early-stage technologies across multiple industries

Dr. Chiu has joined Erbi in 2018 as COO. He has over 25 years of experience in development of innovative and early-stage technologies across multiple industries including semiconductors, optics and life sciences. Prior to joining Erbi, Michael was CTO/VP Engineering at AEi/Mycronic, co-founded Gecko Health and founded Trophos Energy all of which were acquired or sold. He started his career at Teradyne, where he rose to the position of General Manager. Michael earned BSME from the University of Minnesota and MSME, PhD and MBA degrees from the Massachusetts Institute of Technology. Michael has multiple patents and is the recipient of an R&D 100 award.
Head of Cell & Gene Therapy & Bioprocess Applications Development

Kevin Lee, Ph.D.

Dr. Lee formally joined Erbi as co-founder in 2011 but helped develop the core technology platform with Dr. Harry Lee as part of his doctoral research,

Dr. Lee formally joined Erbi as co-founder in 2011 but helped develop the core technology platform with Dr. Harry Lee as part of his doctoral research, which included design of continuous flow microbioreactors and development of a proprietary and patented plastic bonding process that is an enabling technology in Erbi’s bioreactor platform. Kevin also is expert in embedded systems, cell culture and bioengineering and has a B.S.E.E. from the University of California, Los Angeles and a PhD from the Massachusetts Institute of Technology. Kevin is inventor on 6 patents, and has led programs with industry and academia across multiple cell types including e.coli, Pichia, CHO and CAR-T.
Director of Systems Engineering

Blair Morad

Mr. Morad has over 20 years in product development, with 15 years in the life science industry, including cell sorting, cell culturing, and microbial detection.

Mr. Morad has over 20 years in product development, with 15 years in the life science industry, including cell sorting, cell culturing, and microbial detection. Blair has directed multi-discipline teams in creating industry recognized products at Cytonome, Emulate Bio, and most recently Director of New Product Development at Rapid Micro Biosystems, a leader in automated QC microbial detection. Blair has a BSME from the University of Massachusetts, Amherst.
Co-Founder and CTO

Harry Lee, Ph.D.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years. Harry has deep expertise in systems engineering, photonics, embedded systems, cell culture and bioengineering. He has a B.S.E.E. from the University of Michigan and a PhD from the Massachusetts Institute of Technology. Harry is inventor on 8 patents, is the author of multiple publications in the field and has been awarded multiple grants to further develop Erbi’s core technology.
VP of Product Management and Business Development

John Bonham-Carter

Mr. Bonham-Carter is recognized as one of the early pioneers making continuous bioprocessing a manufacturing reality through Refine’s ATF System

Mr. Bonham-Carter is recognized as one of the early pioneers making continuous bioprocessing a manufacturing reality through Refine’s ATF System – a company he sold to Repligen in 2014. Subsequently within Repligen, he forged the future of intensified processing, ensuring that all processes could benefit from exceptionally high productivity processes. Over 20 therapeutic products, from vaccines to gene therapies and proteins, are now commercially manufactured with products that John brought to market. John has edited 2 books on this subject.

John has broad entrepreneurial, product development and BD experience ranging from AI in fermentation prediction, multiple analytical technologies, metabolic modelling and impact on facilities due to process improvement. He is sought after as a technically focused expert to bring new technologies to market and has been a regular international speaker and co-organizer of several cell culture conferences. He now advises several companies and is an active Angel investor.

Operations Manager

Conor McCarron

Conor McCarron manages manufacturing, supply chain, and logistics for Erbi Biosystems. Prior to joining Erbi he spent seven years working in operations and manufacturing engineering

Conor McCarron manages manufacturing, supply chain, and logistics for Erbi Biosystems. Prior to joining Erbi he spent seven years working in operations and manufacturing engineering at Raytheon Integrated Defense Systems where he primarily worked on the manufacturing of high voltage assemblies and radio frequency circuit boards. Conor holds a Bachelors of Science in Mechanical Engineering and Electrical Engineering, as well as a Masters of Engineering In Manufacturing Engineering from Boston University.
Chief Scientific Officer

Brad Hamilton

Brad Hamilton, is the founder and Chief Science Officer at GoodCell, where he oversees all of GoodCell’s scientific programs and technologies. Prior to joining GoodCell, Brad

Brad Hamilton, is the founder and Chief Science Officer at GoodCell, where he oversees all of GoodCell’s scientific programs and technologies. Prior to joining GoodCell, Brad was the Chief Technology Officer for ReproCELL, a multinational stem cell company focused on developing novel stem cell technologies and therapies.

Brad’s work as a founding scientist and director of research for Stemgent helped to develop groundbreaking RNA-mediated cellular reprogramming technologies, as well as applications for the generation of induced pluripotent stem cells from clinically accessible samples such as human skin, blood, and urine.

Brad has both published and presented this work internationally. He is a member of the International Society of Stem Cell Research (ISSCR) and International Society for Cell and Gene Therapy (ISCT). Prior to joining the field of stem cell research, Brad led research programs at RheoGene and Upstate Biotech (acquired by Millipore), focusing on developing novel discovery technologies such as orthogonal, inducible mammalian gene expression switches, and RNAi screening platforms.

Brad holds an MS in biotechnology from the University of Tennessee—Knoxville, as well as a BS in biology from James Madison University.

VP of Sales

Shelly Adams

Shelly Adams directs the commercial development, sales, and marketing functions within Erbi Biosystems. During her distinguished career

Shelly Adams directs the commercial development, sales, and marketing functions within Erbi Biosystems. During her distinguished career of more than 25 years, she has led commercial efforts within the medical device, biotech, pharmaceutical, and contract manufacturing industries. Her passion, creativity, and commitment to satisfy customer needs have led to a remarkable reputation in the industry. Prior to joining Erbi Biosystems, Shelly worked for Abzena, Gallus BioPharmaceuticals, Johnson Mathey, and Avecia Biologics in the CDMO marketplace. During her time in contract manufacturing companies, her sales experience included developing and manufacturing monoclonal antibodies, DNA medicines, microbial biologics, and small molecules. Shelly holds a bachelor’s in Biology from the University of California, San Diego, USA.
Board of Directors

Michael Chiu, Ph.D.

Dr. Chiu has joined Erbi in 2018 as COO. He has over 25 years of experience in development of innovative and early-stage technologies across multiple industries including semiconductors, optics and life sciences. Prior to joining Erbi, Michael was CTO/VP Engineering at AEi/Mycronic, co-founded Gecko Health and founded Trophos Energy all of which were acquired or sold. He started his career at Teradyne, where he rose to the position of General Manager. Michael earned BSME from the University of Minnesota and MSME, PhD and MBA degrees from the Massachusetts Institute of Technology. Michael has multiple patents and is the recipient of an R&D 100 award.

Harry Lee, Ph.D.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years. Harry has deep expertise in systems engineering, photonics, embedded systems, cell culture and bioengineering. He has a B.S.E.E. from the University of Michigan and a PhD from the Massachusetts Institute of Technology. Harry is inventor on 8 patents, is the author of multiple publications in the field and has been awarded multiple grants to further develop Erbi’s core technology.

John Bonham-Carter

Mr. Bonham-Carter is recognized as one of the early pioneers making continuous bioprocessing a manufacturing reality through Refine’s ATF System – a company he sold to Repligen in 2014. Subsequently within Repligen, he forged the future of intensified processing, ensuring that all processes could benefit from exceptionally high productivity processes. Over 20 therapeutic products, from vaccines to gene therapies and proteins, are now commercially manufactured with products that John brought to market. John has edited 2 books on this subject.

John has broad entrepreneurial, product development and BD experience ranging from AI in fermentation prediction, multiple analytical technologies, metabolic modelling and impact on facilities due to process improvement. He is sought after as a technically focused expert to bring new technologies to market and has been a regular international speaker and co-organizer of several cell culture conferences. He now advises several companies and is an active Angel investor.

Joe Gentile

Mr. Gentile has over 30 years of global medical device, diagnostics and life science experience driving growth in developed and emerging markets, enhancing profitability and cash flow, achieving operational excellence, and developing next generation products, services and technologies.  He served on the board or TIE Boston and currently advises multiple life science ventures helping them from startup to successful exit.  Joe has a BSEE from Northeastern University as well as an MSEE and MBA from Boston University.

Mark Erhrman

Dr. Ehrman is an expert in oncology and has built, run and sold an extensive medical practice in this field. He currently develops commercial properties and other investments. Mark has a BA in Mathematics from Princeton University, MSc in Microbiology and Chemistry from NYU, an MD from NYU School of Medicine and a JD from Boston University School of Law.

Scientific Advisory Board

Thomas C. Ransohoff, M.S

Thomas C. Ransohoff, M.S is currently Co-Head, Biologicals Franchise at National Resilience, Inc. (“Resilience”) and has over 30 years of experience in the biopharmaceutical industry. Mr. Ransohoff’s areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Before joining Resilience, Mr. Ransohoff was a Managing Director at BDO and its precursor BPTC, a leading CMC consulting firm that he helped build over a 20 year period. Prior to that, he held senior level positions at TranXenoGen, Dyax, Repligen, and Xoma. He is also a co-founder of several successful start-ups, including 4th Dimension Bioprocess, Tarpon Biosystems and BioFlash Partners. He serves on a number of scientific and professional advisory boards and holds a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.

Rod Rietze, Ph.D.

Dr. Rod Rietze is co-founder and CEO of iVexSol (intelligent Vector Solutions), Inc., a burgeoning viral vector manufacturer founded on a transformative technology that enables the production of stable lentiviral vectors at any scale. Prior to iVexSol, Rod was the Director of Strategic Development and Innovation at Novartis Cell and Gene Therapy (Cambridge, MA), where he supported the clinical development of a number of next-generation cell and gene therapies, including Kymriah™, the first FDA-approved CAR-T cell-based gene therapy.

Before joining Novartis, Rod led research and development teams of both small molecule and cell-based therapeutics at Pfizer Regenerative Medicine (Cambridge, UK) and TxCell SA (Sophia Antipolis, France). During his tenure in academia, Rod co-founded the 400-member Queensland Brain Institute (Brisbane, Australia), where his lab focused on harnessing the regenerative capacity of resident neural stem cells as a means to treat age-related cognitive decline. His work was featured on the front covers of Nature and Science, and received numerous awards including Science Magazine’s “Breakthrough of the Year”.

With over two decades of technical, operational, and strategic leadership experience in the development of novel therapeutics, Rod remains passionate about discovering and delivering innovative technologies and medicines to transform the treatment of disease. He holds a BSc and MSc from the University of Calgary, Canada, and a Ph.D. from The Walter and Eliza Hall Institute of Medical Research (University of Melbourne, Australia).

Bert Frohlich, Ph.D.

Bert Frohlich is a Ph.D. biochemical engineer with over 25 years of experience in the biotechnology, pharmaceutical, and chemical industries; he has been consulting through his own company, Biopharm Designs LLC, for the last four years. Although most of his experience is in the biopharmaceutical CMC space, he served most recently as Vice President of Engineering and Commercialization at BlueNalu Inc., a startup company in the new cell-based meat area. Before becoming a consultant, he held director-level positions at Shire, Amgen, EMD, and Acambis (now Sanofi) and worked as a senior engineer at Genzyme, Biometics, and Roche in process/facility design, bioprocess development, and manufacturing technical services. Over the course of his career, Bert introduced a variety of products to manufacturing through the scale-up and tech transfer of cell culture and other processes. In addition to advising on strategic direction in process and manufacturing technology, he now also helps clients design and implement high-level business processes, including cost modeling and quality-by-design, towards improving work efficiency, costs, timelines, and product quality.

Rajeev J. Ram

Rajeev J. Ram has worked in the areas of physical optics and electronics for much of his career. In the early 1990’s, he developed the III‑V wafer bonding technology that led to record brightness light emitting devices at Hewlett-Packard Laboratory in Palo Alto. While at HP Labs, he worked on the first commercial deployment of surface emitting lasers. In the early 1990’s, he developed the first semiconductor laser without population inversion, semiconductor lasers that employ condensation of massive particles, and threshold-less lasers.

Since 1997, Ram has been on the Electrical Engineering faculty at the Massachusetts Institute of Technology (MIT) and a member of the Research Laboratory of Electronics. He has served on the Defense Sciences Research Council advising DARPA on new areas for investment and served as a Program Director at the newly founded Advanced Research Project Agency-Energy. At ARPA‑e, he managed a research portfolio exceeding $100M and consulted with the Office of Science and Technology Policy and the White House.

His group at MIT has developed record energy-efficient photonics for microprocessor systems, microfluidic systems for the control of cellular metabolism, and the first light-source with greater than 100% electrical-to-optical conversion efficiency. His group’s work on small-scale solar thermoelectric generation is being deployed for rural electrification in the developing world as SolSource and was recognized with the St. Andrews Prize for Energy and the Environment.

Ram holds degrees in Applied Physics from California Institute of Technology and Electrical Engineering from the University of California, Santa Barbara.